UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF) shares gapped up before the market opened on Tuesday . The stock had previously closed at $250.88, but opened at $258.4650. UCB shares last traded at $252.16, with a volume of 84 shares changing hands.

Analysts Set New Price Targets

UCBJF has been the subject of a number of research analyst reports. Jefferies Financial Group upgraded UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company’s fifty day moving average is $277.48 and its two-hundred day moving average is $292.61.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.